ReviewAdvances in therapy2026
Sacral Neuromodulation for Refractory Overactive Bladder: Closing the Gaps in Anatomy, Mechanisms, and Parameter Selection.
Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sacral neuromodulation is an effective therapy to control overactive bladder symptoms, yet the underlying mechanisms and optimal stimulation parameters remain unclear. Analysis of 45 clinical studies from 1994 to 2023 demonstrated no significant change in rates of long-term symptom control despite technological advancements, and analysis of recent studies (2015 onward) showed that more than 40% of patients receiving test stimulation do not benefit from sacral neuromodulation. Critical knowledge gaps persist. A lack of evidence guiding stimulation parameter selection has resulted in largely unchanged programming protocols since initial US Food and Drug Administration (FDA) approval in 1997. There is little knowledge of sacral nerve anatomy or nerve fiber organization, and the specific neural pathways mediating therapeutic effects remain unclear. Additionally, there is a limited understanding of how anatomical variations affect stimulation outcomes and few validated predictors of long-term success. We propose that developing detailed computational models incorporating realistic nerve morphology and tissue properties, combined with systematic documentation of programming parameters and outcomes will enable development of more effective stimulation protocols and electrode designs. Bridging these knowledge gaps is essential for improving the consistency and efficacy of sacral neuromodulation for refractory overactive bladder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.